Short Interest in Xenetic Biosciences, Inc. (NASDAQ:XBIO) Declines By 51.2%

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the recipient of a large decrease in short interest in April. As of April 30th, there was short interest totaling 7,266 shares, a decrease of 51.2% from the April 15th total of 14,880 shares. Based on an average trading volume of 16,053 shares, the short-interest ratio is presently 0.5 days. Approximately 0.3% of the company’s stock are sold short.

Xenetic Biosciences Stock Down 2.3%

Xenetic Biosciences stock opened at $3.04 on Friday. The company has a market capitalization of $6.96 million, a P/E ratio of -2.53 and a beta of 2.20. The stock’s 50 day moving average is $3.02 and its 200 day moving average is $2.63. Xenetic Biosciences has a twelve month low of $1.90 and a twelve month high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.20) earnings per share for the quarter. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.The company had revenue of $0.81 million during the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Trading of Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC bought a new stake in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned about 0.60% of Xenetic Biosciences at the end of the most recent quarter. Institutional investors own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.